UNSPSC 51352411: Mestranol/norethynodrel

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.

UNSPSC 51352411 Mestranol/norethynodrel is a Commodity code covering oral contraceptive pharmaceuticals. State and local governments procure these products primarily through pharmacy benefit programs, cooperative purchasing alliances, and health and human services agencies that manage employee health plans, Medicaid programs, and institutional pharmacy needs. The solicitations under this code show two distinct procurement models: direct-to-manufacturer arrangements negotiated outside traditional pharmacy benefit manager (PBM) and group purchasing organization (GPO) channels, and cooperative purchasing contracts that aggregate demand across multiple state and local jurisdictions to secure competitive generic pricing. Issuing bodies include state health and human services departments (notably Texas HHS Commission) and multistate cooperative purchasing alliances (MMCAP, administered by the Minnesota Department of Administration). These entities source mestranol/norethynodrel and other contraceptive medications as part of broader pharmaceutical inventory management supporting employee group health plans, state Medicaid programs, and institutional pharmacy operations.

The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, which targets negotiated net pricing and value-based agreements outside traditional PBM and GPO arrangements—a model designed to reduce prescription fulfillment costs by establishing direct relationships between state agencies and manufacturers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon; awarded vendors must supply products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with contracts effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness. Recent activity centers on Texas and the Upper Midwest (Minnesota and Oregon), with procurement emphasis on cost management, therapeutic alternatives, and supply chain security compliance (cGMP, DSCSA).